The white-tailed deer was found near Optima, in the Oklahoma Panhandle, after a Texas County landowner told officials it had been behaving abnormally.
Wisconsin's latest case is from another deer farm, and the positive finding in Texas marks the first from Bexar County.
The hunter from Louisville legally harvested the 8-point buck in Wisconsin, then brought the intact head into Kentucky for taxidermy, which violates Kentucky law.
This is the eleventh CWD-affected deer farm in the state over the past 15 years.
The 11 new cases raise the state's total since the virus was first detected early last year to 12.
The wild deer—a 3-year-old doe —tested positive in the town of Nepeuskun.
CWD has been confirmed at deer-breeding facilities in Hamilton and Frio counties.
The detections span locations in three counties, with cases in two identified through postmortem testing.
For the first time, chronic wasting disease has been detected in white-tailed deer in Manitoba—previous detections were in mule deer.
Testing done on samples from about 5,000 deer harvested in last year's hunting seasons in Iowa revealed that 84 deer were positive for CWD.
In North Carolina, officials confirm the first case detected outside of the state's surveillance area.
Earlier this month, officials confirmed CWD in Sheboygan County, and in January CWD was detected for the first time in Waupaca County.
The shortage is leading to delays in the testing of deer samples submitted by hunters.
The deer was a 2-year-old doe harvested by a hunter in the northwestern part of the county.
A buck brought to a taxidermist represents the first CWD case in Fairfax County, Virginia.
Researchers describe a CWD strain from a moose in Finland that's distinct not only from CWD prions in North America but also from those in neighboring Norway.
CWD has been detected on a deer farm in Lincoln County in the north central part of the state.
A study of US patients aged 0 to 20 years hospitalized for COVID-19 or multisystem inflammatory syndrome in children (MIS-C) in 2020 and 2021 shows that 22% had a neurologic condition, including 9% with life-threatening illness.
A new study published in eClinicalMedicine analyzed 19 studies on monkeypox, which included 7,553 reported cases, among which there were 555 hospitalizations. The meta-analysis suggests monkeypox patients have a 14.1% hospitalization rate.
Children who had an underlying illness were at greatest risk for severe COVID-19 and death, but those who were vaccinated were fairly well protected, according to an observational study presented this week at the American Academy of Pediatrics (AAP) National Conference & Exhibition in Anaheim, California.
In its latest weekly update on the pandemic, the World Health Organization (WHO) said today that global COVID-19 cases declined 6% last week compared to the previous week, though the pace of activity increased in the European region, which experienced an 8% rise compared to the week before.
High-flow oxygen didn't significantly lower death rates beyond those of standard oxygen therapy in COVID-19 patients with respiratory failure, according to a multicenter randomized clinical trial published yesterday in JAMA.
In the first known estimate of the SARS-CoV spillover risk from bats to people, researchers who studied bat populations in South East Asia and interactions with humans estimate that about 66,280 people a year are infected each year. The team, based at EcoHealth Alliance, published their findings today in Nature Communications.
The sensitivity of home rapid antigen COVID-19 tests peaks 4 days after symptom onset, suggesting that a negative antigen test should be followed by a second test in 1 or 2 days, according to a prospective study published today in JAMA Internal Medicine.
Three new studies to be presented at the upcoming European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) conference at the end of the month demonstrate benefits of the antiviral molnupiravir against COVID-19 infections, including evidence that Merck's pill reduces symptoms of the SARS-CoV-2 virus by day 3 of administration.
